Gene Therapy Market Scenario
Increasing funding for gene therapy research, technological advancements in the field of Gene Therapy and high incidence of cancer and other target diseases are some of the major factors propelling the gene therapy market globally. Furthermore, several initiatives have been undertaken by biopharma companies is also one of the factor propelling the growth of Gene Therapy market. However, the high prices of currently available therapies incentivize therapy is one of the major factor expected to hamper the global growth of the market.
Gene Therapy Market Segmentation
The Gene Therapy market is segmented by vector, indication, delivery method and geography. The vectors studied in the Gene Therapy market are Non-Viral Vectors (Oligonucleotides and Other Non-Viral Vectors), and Viral Vectors (Retroviral Vectors (Gamma-Retroviral Vectors and Lentiviral Vectors), Adeno-Associated Virus Vectors and Other Viral Vectors. Furthermore, various indication of Gene Therapy are Cancer, Duchenne Muscular Dystrophy, Hepatological Diseases, Neurological Diseases and Other Indications. Likewise, the delivery method comprises of In Vivo Gene Therapy and Ex Vivo Gene Therapy. Based on Geography, the Gene Therapy Market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and RoW.
Gene Therapy Market by Geography
Based on geography, the Gene Therapy market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and RoW. Among all the regions, the North America is anticipated to hold the major share of the global gene therapy market. Major drivers include high adoption of advanced techniques, strong regulatory framework, higher healthcare expenditure, and availability of skilled professionals. Likewise, the U.S. holds the largest market share owing to factors such as highly developed healthcare infrastructure and presence of centers & institutes engaged in R&D on gene therapies.
Gene Therapy Market Key Players
Some of the major players operating in the global Gene Therapy market includes Agtc (Applied Genetic Technologies Corporation), Amgen, Inc., Anges, Inc., Biogen, Bluebird Bio, Inc., Celgene Corporation (A Bristol-Myers Squibb Company), Cellectis, Dynavax Technologies, Gensight Biologics S.A., Gilead Sciences, Inc., Human Stem Cells Institute, Jazz Pharmaceuticals Plc, Molmed S.P.A., Mustang Bio, Novartis Ag, Orchard Therapeutics Plc, Poseida Therapeutics, Inc., Sangamo Therapeutics, Sarepta Therapeutics, Shanghai Sunway Biotech Co., Ltd., Sibiono Genetech Co., Ltd., Spark Therapeutics, Inc. (A Part Of F. Hoffmann-La Roche) and Uniqure N.V. Many companies in this market implement initiatives such as mergers and acquisitions, product developments, and geographic penetration to compete in the market.
Gene Therapy Market Report Key Benefits